Cancer cell-associated fatty acid synthase activates endothelial cells and promotes angiogenesis in colorectal cancer

Carcinogenesis

Volumn 35, Issue 6, 2014, Pages 1341-1351

  Zaytseva, Yekaterina Y ^a   Elliott, Victoria A ^a   Rychahou, Piotr ^a,b   Mustain, W Conan ^b   Kim, Ji Tae ^a,b   Valentino, Joseph ^b   Gao, Tianyan ^b   O'Connor, Kathleen L ^a   Neltner, Janna M ^b   Lee, Eun Y ^a,b   Weiss, Heidi L ^a,c   Mark Evers, B ^a,b  

^a UNIVERSITY OF KENTUCKY   (United States)

^b UNIVERSITY OF KENTUCKY   (United States)

^c UNIVERSITY OF KENTUCKY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FATTY ACID SYNTHASE; GELATINASE B; MATRIGEL; UNCLASSIFIED DRUG; VASCULOTROPIN; VASCULOTROPIN 165B; VASCULOTROPIN 189; VASCULOTROPIN A; VASCULOTROPIN RECEPTOR 2;

ANGIOGENESIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CAPILLARY DENSITY; CARCINOGENESIS; CELL MIGRATION; CELL PROLIFERATION; CELLULAR SECRETION; CHICK EMBRYO; CHORIOALLANTOIS; COCULTURE; COLORECTAL CANCER; CONDITIONED MEDIUM; CONFOCAL MICROSCOPY; CONTROLLED STUDY; DOWN REGULATION; EMBRYO; ENDOTHELIUM CELL; ENZYME ACTIVITY; ENZYME LINKED IMMUNOSORBENT ASSAY; GENE EXPRESSION; GENE SILENCING; HCT116 CELL LINE; HT 29 CELL LINE; IMMUNOFLUORESCENCE TEST; IMMUNOHISTOCHEMISTRY; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN SECRETION; TUMOR VASCULARIZATION; UPREGULATION; ANIMAL; COLORECTAL TUMOR; DISEASE MODEL; GENE EXPRESSION REGULATION; GENETICS; HUMAN; METABOLISM; NEOVASCULARIZATION (PATHOLOGY); PATHOLOGY; SIGNAL TRANSDUCTION; TUMOR CELL LINE; XENOGRAFT;

ANIMALS; CELL LINE, TUMOR; CHICK EMBRYO; COLORECTAL NEOPLASMS; DISEASE MODELS, ANIMAL; ENDOTHELIAL CELLS; FATTY ACID SYNTHASES; GENE EXPRESSION REGULATION; GENE KNOCKDOWN TECHNIQUES; HETEROGRAFTS; HUMANS; MALE; MATRIX METALLOPROTEINASE 9; NEOVASCULARIZATION, PATHOLOGIC; SIGNAL TRANSDUCTION; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-2;

EID: 84905380433     PISSN: 01433334     EISSN: 14602180     Source Type: Journal    
DOI: 10.1093/carcin/bgu042     Document Type: Article

References (36)

1. Jemal, A. et al. (2011) Global cancer statistics. Cancer J. Clin., 61, 69-90.
2. Kuhajda, F.P. (2006) Fatty acid synthase and cancer: new application of an old pathway. Cancer Res., 66, 5977-5980.
3. Zhan, Y. et al. (2008) Control of cell growth and survival by enzymes of the fatty acid synthesis pathway in HCT-116 colon cancer cells. Clin. Cancer Res., 14, 5735-5742.
4. Uddin, S. et al. (2009) High prevalence of fatty acid synthase expression in colorectal cancers in Middle Eastern patients and its potential role as a therapeutic target. Am. J. Gastroenterol., 104, 1790-1801.
5. Camassei, F.D. et al. (2003) Expression of the lipogenic enzyme fatty acid synthase (FAS) in retinoblastoma and its correlation with tumor aggressiveness. Invest. Ophthalmol. Vis. Sci., 44, 2399-2403.
6. Zaytseva, Y.Y. et al. (2012) Inhibition of fatty acid synthase attenuates CD44-associated signaling and reduces metastasis in colorectal cancer. Cancer Res., 72, 1504-1517.
7. Migita, T. et al. (2009) Fatty acid synthase: a metabolic enzyme and candidate oncogene in prostate cancer. J. Natl Cancer Inst., 101, 519-532.
8. Joyce, J.A. et al. (2009) Microenvironmental regulation of metastasis. Nat. Rev. Cancer, 9, 239-252.
9. Dvorak, H.F. et al. (2011) Tumor microenvironment and progression. J. Surg. Oncol., 103, 468-474.
10. Potente, M. et al. (2011) Basic and therapeutic aspects of angiogenesis. Cell, 146, 873-887.
11. Folkman, J. et al. (1987) Angiogenic factors. Science, 235, 442-447.
12. Butler, J.M. et al. (2010) Instructive role of the vascular niche in promoting tumour growth and tissue repair by angiocrine factors. Nat. Rev. Cancer, 10, 138-146.
13. Ferrara, N. et al. (2003) The biology of VEGF and its receptors. Nat. Med., 9, 669-676.
14. Des Guetz, G. et al. (2006) Microvessel density and VEGF expression are prognostic factors in colorectal cancer. Meta-analysis of the literature. Br. J. Cancer, 94, 1823-1832.
15. Olsson, A.K. et al. (2006) VEGF receptor signalling-in control of vascular function. Nat. Rev. Mol. Cell Biol., 7, 359-371.
16. Crawford, Y. et al. (2009) VEGF inhibition: insights from preclinical and clinical studies. Cell Tissue Res., 335, 261-269.
17. Zigmond, E. et al. (2011) Utilization of murine colonoscopy for orthotopic implantation of colorectal cancer. PLoS One, 6, e28858.
18. Deryugina, E.I. et al. (2008) Chick embryo chorioallantoic membrane model systems to study and visualize human tumor cell metastasis. Histochem. Cell Biol., 130, 1119-1130.
19. Folkman, J. et al. (1989) Induction of angiogenesis during the transition from hyperplasia to neoplasia. Nature, 339, 58-61.
20. Nowak, D.G. et al. (2008) Expression of pro-and anti-angiogenic isoforms of VEGF is differentially regulated by splicing and growth factors. J. Cell Sci., 121(Pt 20), 3487-3495.
21. Lee, S. et al. (2005) Processing of VEGF-A by matrix metalloproteinases regulates bioavailability and vascular patterning in tumors. J. Cell Biol., 169, 681-691.
22. Uthoff, S.M. et al. (2002) VEGF isoforms and mutations in human colorectal cancer. Int. J. Cancer, 101, 32-36.
23. Díaz, R. et al. (2008) p73 Isoforms affect VEGF, VEGF165b and PEDF expression in human colorectal tumors: VEGF165b downregulation as a marker of poor prognosis. Int. J. Cancer, 123, 1060-1067.
24. Cressey, R. et al. (2005) Alteration of protein expression pattern of vascular endothelial growth factor (VEGF) from soluble to cell-associated isoform during tumourigenesis. BMC Cancer, 5, 128.
25. Hawinkels, L.J. et al. (2008) VEGF release by MMP-9 mediated heparan sulphate cleavage induces colorectal cancer angiogenesis. Eur. J. Cancer, 44, 1904-1913.
26. Park, J.E. et al. (1993) The vascular endothelial growth factor (VEGF) isoforms: differential deposition into the subepithelial extracellular matrix and bioactivity of extracellular matrix-bound VEGF. Mol. Biol. Cell, 4, 1317-1326.
27. Ferrara, N. (2002) VEGF and the quest for tumour angiogenesis factors. Nat. Rev. Cancer, 2, 795-803.
28. Belotti, D. et al. (2003) Matrix metalloproteinases (MMP9 and MMP2) induce the release of vascular endothelial growth factor (VEGF) by ovarian carcinoma cells: implications for ascites formation. Cancer Res., 63, 5224-5229.
29. Bryan, B.A. et al. (2010) RhoA/ROCK signaling is essential for multiple aspects of VEGF-mediated angiogenesis. FASEB J., 24, 3186-3195.
30. Ferrara, N. (2002) Role of vascular endothelial growth factor in physiologic and pathologic angiogenesis: therapeutic implications. Semin. Oncol., 29 (6 suppl. 16), 10-14.
31. Seguin, F. et al. (2012) The fatty acid synthase inhibitor orlistat reduces experimental metastases and angiogenesis in B16-F10 melanomas. Br. J. Cancer, 107, 977-987.
32. Tokunaga, T. et al. (1998) Vascular endothelial growth factor (VEGF) mRNA isoform expression pattern is correlated with liver metastasis and poor prognosis in colon cancer. Br. J. Cancer, 77, 998-1002.
33. Zöller, M. (2011) CD44: can a cancer-initiating cell profit from an abundantly expressed molecule? Nat. Rev. Cancer, 11, 254-267.
34. Hanahan, D. et al. (2012) Accessories to the crime: functions of cells recruited to the tumor microenvironment. Cancer Cell, 21, 309-322.
35. Ebos, J.M. et al. (2011) Antiangiogenic therapy: impact on invasion, disease progression, and metastasis. Nat. Rev. Clin. Oncol., 8, 210-221.
36. Liu, H. et al. (2010) Biochemistry, molecular biology, and pharmacology of fatty acid synthase, an emerging therapeutic target and diagnosis/prognosis marker. Int. J. Biochem. Mol. Biol., 1, 69-89.